Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer

NEXT STORY
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
PREV STORY
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

author_avatar
NASDAQ Market News

Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme

author_avatar
NASDAQ Market News

Immunocore Limited: Appoints Paul Fry as Chief Financial Officer

ABINGDON, OXON, United Kingdom, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Immunocore Limited, a world-leading ...

author_avatar
NASDAQ Market News